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Abstract  
 
Age is a critical factor in the prevalence of tauopathies, including Alzheimer’s disease. To 
observe how an ageing phenotype interacts with and affects the pathological intracellular 
accumulation of hyperphosphorylated tau, the tauopathy mouse model pR5 (expressing 
P301L mutant human tau) was back-crossed more than ten times onto a senescence-
accelerated SAMP8 background to establish the new strain, SApT. Unlike SAMP8 mice, pR5 
mice are characterised by a robust tau pathology particularly in the amygdala and 
hippocampus. Analysis of age-matched SApT mice revealed that pathological tau 
phosphorylation was increased in these brain regions compared to those in the parental pR5 
strain. Moreover, as revealed by immunohistochemistry, phosphorylation of critical tau 
phospho-epitopes (P-Ser202/P-Ser205 and P-Ser235) was significantly increased in the 
amygdala of SApT mice in an age-dependent manner, suggesting an age-associated effect of 
tau phosphorylation. Anxiety tests revealed that the older cohort of SApT mice (10 months 
versus 8 months) exhibited a behavioural pattern similar to that observed for age-matched tau 
transgenic pR5 mice and not the SAMP8 parental mice. Learning and memory, however, 
appeared to be governed by the accelerated ageing background of the SAMP8 strain, as at 
both ages investigated, SAMP8 and SApT mice showed a decreased learning capacity 
compared to pR5 mice. We therefore conclude that accelerated aging exacerbates 
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pathological tau phosphorylation, leading to changes in normal behaviour. These findings 
further suggest that SApT mice may be a useful novel model in which to study the role of a 
complex geriatric phenotype in tauopathy. 
 
Running title: P301L tau expression on a SAMP8 background 
Key words: Ageing; frontotemporal dementia; geriatric condition; senescence; tau; 
transgenic.  
 
Introduction 
  
Age is the most important risk factor for neurodegenerative diseases, with the 
numbers of patient affected by diseases such as Alzheimer’s disease (AD) or frontotemporal 
lobar degeneration (FTLD) projected to increase significantly in the coming years. However, 
no cure is available for any of these conditions (Winblad et al. 2016; Holtzman et al. 2012). 
There are several reasons that make the treatment of age-associated diseases of the brain 
particularly challenging, including a long disease duration that is often associated with the 
subtle onset of clinical symptoms (Leinenga et al. 2016). This is also reflected by a paucity of 
animal models that reproduce the complexity of these conditions (Ittner et al. 2015). 
 A common hallmark of tauopathies (such as AD and a major subset of FTLD termed 
FTLD-tau) is the pathological intracellular accumulation of the microtubule-associated 
protein tau in brain regions that are involved in learning and memory, such as the amygdala 
and the hippocampus (Goedert & Spillantini 2006). There, tau is found in a 
hyperphosphorylated state that alters the normal neuronal physiology (Bodea et al. 2016). 
The modelling of tau pathology in animals has been facilitated by the identification of 
pathogenic mutations in the tau-encoding MAPT gene in familial cases of FTLD-tau. The 
pR5 mouse line overexpresses the P301L mutation using the longest human tau isoform 
under the control of the neuron-specific mouse Thy1.2 promoter. In these mice, pronounced 
tau hyperphosphorylation is initially detected in the amygdala and subsequently in the CA1 
region of the hippocampus, resulting in behavioural impairments in amygdala- and 
hippocampus-dependent functions (Pennanen et al. 2006).  
 Ageing has been modelled in senescence-accelerated mice that present with a 
multigenic phenotype. One of the more frequently used strains is the senescence-accelerated 
prone 8 (SAMP8) strain that displays features of accelerated ageing such as hair loss, reduced 
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activity and lordokyphosis (Takeda 1999). In addition, these mice have a reduced mean life 
expectancy (10 months versus 22 months in senescence-resistant SAMR1 controls), and 
exhibit increased oxidative stress and gliosis (Pallas et al. 2008; Alvarez-García et al. 2006). 
There are also reports of increased tau hyperphosphorylation and deposits that bear a 
resemblance to the amyloid plaques that are found in AD (Takemura et al. 1993; Canudas et 
al. 2005). However, we previously failed to detect tau hyperphosphorylation in our SAMP8 
colony compared to SAMR1 mice (Delerue et al. 2013). Behaviourally, SAMP8 mice display 
hyperactivity as early as four months of age, when assessed in the open-field test or the 
elevated plus maze (Markowska et al. 1998).  
 Here, we aimed to combine the two factors, tau pathology and accelerated ageing, by 
crossing the tau hyperphosphorylation-prone pR5 mouse line onto a senescence-accelerated 
SAMP8 background and going through more than ten rounds of successive cross-breeding to 
obtain a senescence-accelerated phospho-tau prone line (termed SApT). Analysing two 
cohorts of mice (with a median age of 7.8 months or 9.9 months), we assessed tau 
phosphorylation in the SApT mice. Focusing on the amygdala as a site of prominent 
pathology in pR5 mice (Deters et al. 2008), we found increased tau phosphorylation when 
compared to the parental pR5 strain (or the SAMP8 mice that showed no tau pathology), a 
phenotype that was accentuated with age, as revealed by immunohistochemistry.  The older 
cohort of SApT mice showed increased anxiety compared with age-matched SAMP8 mice, 
whereas their already diminished learning capacity due to the SAMP8 background was not 
reduced further. Thus, we were able to demonstrate that accelerated ageing increases tau 
pathology, leading to alterations of the histopathology-associated behaviour.  
 
Results 
 
Generation of the new SApT mouse line 
 
To evaluate the impact of senescence on tau phosphorylation, the senescence-accelerated 
SAMP8 mouse strain was crossed with the P301L tau transgenic hyperphosphorylated tau-
prone pR5 model for at least 10 generations, obtaining a new line, referred to here as the 
senescence-accelerated phospho-tau (SApT) line (Fig. 1a). The presence of the P301L tau 
transgene was determined by PCR (data not shown) and the expression of human tau 
expression was confirmed by western blotting of brain extracts using the human tau-specific 
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monoclonal antibody HT7 (Fig. 1b). Thus, we obtained a novel mouse strain that allowed us 
to determine the extent to which the phenotypes of the parental lines SAMP8 and pR5 were 
recapitulated and accentuated.  
 
Increased tau phosphorylation in brain lysates of SApT mice  
 
Previous studies reported pronounced levels of tau phosphorylation at specific sites in pR5 
mice at around 6 months of age (Bi et al. 2011). Therefore, to evaluate the impact of ageing 
on tau phosphorylation at a time when the pathology develops, we used two groups of 
animals, one with a median age of 7.8 months and an older cohort with a median age of 9.9 
months. We evaluated the state of tau proteins by assessing a comprehensive list of phospho-
epitopes: P-Ser202/P-Thr205 (‘AT8’ epitope), P-Thr231/P-Ser235 (AT180), P-Thr181 
(AT270), P-Ser235, P-Ser404 and P-Ser422 (Fig. 2). Our western blot data revealed a 
significant increase in immunoblot reactivity for the AT270 (p<0.05) (Fig. 2c) and Ser404 
(p<0.01) (Fig. 2e) epitopes in the older SApT mice compared with SAMP8. Moreover, an 
age-associated effect was observed in the SApT mice in regards to P-Thr181 (p<0.001) (Fig. 
2c), P-Ser404 (p<0.01) (Fig. 2e), as well as P-Ser422 immunoreactivity (p<0.05) (Fig. 2f).  
These data indicate that tau phosphorylation is accelerated in the SApT mice due to the 
presence of both a geriatric and a genetic predisposition given by the parental lines.  
 
Increased tau phosphorylation in the amygdala of SApT mice 
 
We next investigated the levels of hyperphosphorylated tau in specific brain regions using 
immunohistochemistry. In pR5 mice, robust pathological tau phosphorylation is evident at 
around 6 months of age. This is initiated in the amygdala and subsequently appears in the 
hippocampus (Deters et al. 2008; Pennanen et al. 2004). We therefore performed an 
immunohistochemical analysis using the AT8, AT180 and P-Ser235 antibodies on brain 
sections obtained from  SApT, pR5 and SAMP8 mice, analysing the same two age groups as 
for the western blot analysis (Fig. 3). SAMP8 animals displayed virtually no 
immunoreactivity for any of the antibodies used, whereas pR5 mice showed confined areas of 
immunoreactivity that was already present in the younger age group. The SApT mice 
displayed massively increased levels of tau phosphorylation in the amygdala, with lower or 
no immunoreactivity being detected in the hippocampus and cortex. More specifically, in the 
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pR5 amygdala, the level of AT8 was significantly increased (p<0.001) compared with that in 
the SAMP8 mice for both age groups.In comparison with the SApT animals, same mice 
displayed a lower, but still significant (p<0.05) difference in tau phosphorylation, that was 
further accentuated in the older group (p<0.001). Interestingly, we were able to identify a 
significant increase (p<0.001) in the stained area in the older compared with younger SApT 
animals, indicative of an age-related effect in these animals (Fig. 3a). We were not able to 
observe any changes in phosphorylation levels in the hippocampus or cortex of SApT versus 
pR5 mice using the AT8 antibody. The SApT mice displayed an increased AT8 
immunoreactivity (p<0.05) in the hippocampus compared with the SAMP8 mice in both the 
younger and older cohorts.  
A similar pattern of reactivity was recorded for AT180 (Fig. 3b), although we did not 
identify any difference between the two age groups of SApT mice. Interestingly, AT180 
revealed increased reactivity in the cortex of SApT compared with SAMP8 mice at the 
younger age (p<0.05) (Fig. 3b); however, a higher variation in cortical reactivity was 
observed in the older animals for this genotype. To strengthen our findings, the staining 
pattern observed in the amygdala was confirmed with a third antibody, raised against 
phosphorylated Ser235 of tau (an epitope also recognised by the AT180 antibody). Again, 
using this antibody we saw an increase in immunostaining in the older versus the younger 
SApT mice (p<0.001) (Fig. 3c). By targeting P-Ser235, we were able to identify an increased 
reactivity in the cortex of old SApT versus SAMP8 mice (p<0.01); however no 
immunoreactivity was evident in the hippocampus (Fig. 3c).   
Together, these data reveal that the regions most affected by tau phosphorylation in 
SApT animals are the amygdala and, to a much lesser extent, the hippocampus. The 
pathology in the SApT mice was more pronounced than that seen in the pR5 mice, and it was 
accentuated with age. Given that in our hands the SAMP8 mice displayed tau 
phosphorylation that was below detection levels, as previously reported  (Delerue et al. 
2013), we conclude that the SAMP8 background confers a geriatric predisposition towards 
increased tau phosphorylation in P301L tau-expressing mice. This led us to hypothesise that 
behaviour associated with the affected brain anatomical regions would also be affected. 
 
Increased anxiety in SApT and pR5 mice 
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The amygdala and hippocampus are among the initial structures that are affected by 
tau pathology in AD, affecting cognitive processes such as anxiety and memory (Cavedo et 
al. 2014; Poulin et al. 2011). Thus, we investigated whether SApT mice present with specific 
behavioural changes compared with the SAMP8 and pR5 lines. To determine whether any of 
the lines displayed differences in their basic behaviour and locomotor activity, we used a 
modified SHIRPA protocol (that includes visual acuity) as a primary behavioural screen 
(Rogers et al. 1997; Filali & Lalonde 2009), followed by an assessment of grip strength, 
motor coordination and balance on the accelerated Rotarod (van der Jeugd et al. 2016). 
Besides an increased weight in the older pR5 group, no other phenotypical, muscular or 
locomotor differences were observed between the three strains at the ages investigated (Fig 
4a-c).  
Next, the elevated plus maze test was used to assess amygdala-related anxiety levels 
(Fig. 5). Our results revealed that the mice presenting with increased levels of 
hyperphosphorylated tau in the amygdala spent more time in the closed arm of the maze, 
indicative of an increased level of anxiety compared with the SAMP8 mice (Fig. 5a). 
However, the difference was only significant for the older mice the pR5 and SApT mice were 
compared with the SAMP8 (p<0.05) (Fig. 5b).   
Together, these data support our histological analysis, proving that the accumulation 
of hyperphosphorylated tau in the amygdala alters the behaviour of the affected mice as they 
age.  
 
Decreased ability of the SApT and SAMP8 mice to learn  
 
Given that we observed increased tau phosphorylation in the hippocampus of SApT 
mice compared to the parental strains, we next assessed their learning and memory using the 
active place avoidance (APA) task. Even though in all groups learning did not improved in 
the final day of the testing, we observed a marked difference between the SApT and SAMP8 
mice compared with the pR5 mice on all days of testing, independent of the age group (Fig. 
6). Both the SApT and SAMP8 mice received a similar number of shocks, which was 
significantly higher than that recorded for the pR5 group (Fig. 6a). When assessing the time 
to first entry into the shock zone and the maximum avoidance time between shocks (both 
alternative measures of learning), we were unable to see any improvement in the SApT or 
	 7	
SAMP8 mice. Interestingly, the pR5 mice generally performed significantly better compared 
with the SApT or SAMP8 mice (Fig. 6b & c). 
Based on these findings, we conclude that the inability of the SApT mice to memorise 
the spatial cues in the room reached a plateau owing to their SAMP8 background.  
 
Discussion  
 
The novel SApT mouse model was obtained by back-crossing pR5 transgenic mice 
onto a SAMP8 background. SAMP8 mice provide an excellent model for the study of 
senescence (Morley et al. 2012), whereas the pR5 strain models the hyperphosphorylation of 
tau that eventually leads to its deposition into neurofibrillary tangles, a characteristic of 
tauopathies (Ballatore et al. 2007). By establishing the SApT strain, we aimed to assess the 
effect of senescence on tau hyperphosphorylation and behaviour. This study provided 
evidence that senescence can contribute to the accelerated hyperphosphorylation of tau, 
which can lead to the development of behavioural changes.   
Age is the major risk factor for the development of neurodegenerative diseases. Of 
these, AD and a major subtype of FTLD, FTLD-tau, are highly prevalent, with both being 
characterised by an abnormal accumulation of hyperphosphorylated tau in brain regions 
associated with anxiety, learning and memory. We observed increased levels of tau 
phosphorylation in total brain lysates and a specific accumulation in the amygdala and, to a 
lesser extent, in the hippocampus of the SApT mice, reflecting what has previously been 
reported in the parental pR5 strain (Pennanen et al. 2004; Deters et al. 2008). However, tau 
phosphorylation in the SApT mice exceeded the levels in pR5 mice, suggesting an effect 
induced by the presence of the senescence-accelerated background. In line with another study 
(Delerue et al. 2013), we did not find changes of tau phosphorylation in our SAMP8 cohort , 
even though others had reported increased tau phosphorylation by western blot detection 
whencompared with the SAMR1 strain (Canudas et al. 2005; Orejana et al. 2013). Because 
age is a major driver in tau pathology, we expected that a senescent animal in which the 
normal physiology of tau is altered (as for the P301L mutant) would experience a faster rate 
of pathological tau phosphorylation. Interestingly, in a related mouse model resulting from 
crossing SAMP8 mice for at least five generations with an amyloid-β plaque-bearing mouse 
line, APP/PS1, senescence also exacerbated the amyloid pathology in the absence of any 
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behavioural alteration in the object recognition test when compared with the SAMP8 and 
APP/PS1 parental lines (Porquet et al. 2015).  
 Here, we compared the SApT animals with the parental strains SAMP8 and pR5 at 
two different ages. Our biochemical analysis revealed an increase in tau phosphorylation in 
specific brain areas (such as the amygdala) in the SApT mice for both age groups compared 
with age-matched pR5 mice. Importantly, we were able to observe an increase in tau 
phosphorylation levels in the SApT strain, that was accentuated with age. We therefore used 
two behavioural paradigms to investigate the impact of tau accumulation in different brain 
regions in both the younger and the older cohort.  
To assess changes in amygdala-related anxiety behaviour, we used the elevated plus 
maze as a measure of the natural fear that rodents display towards an open environment. In 
this task, the SApT mice showed a gradual increase in anxiety that reached significant levels 
only in the older age group versus age-matched SAMP8 mice, and a similar level to that 
observed in the pR5 mice. Interestingly, it is known that SAMP8 mice present with a reduced 
anxiety-like behaviour compared with SAMR1 mice (Miyamoto et al. 1992; Markowska et 
al. 1998). In our study, however, we were able to alter this behaviour by introducing the 
P301L mutated human tau onto the SAMP8 background.  
In relation to the learning capacity of the SApT animals, we observed a marked 
similarity with the SAMP8 group, but not the pR5 mice. Others have used active avoidance 
tests to demonstrate that the SAMP8 mice display learning deficits that are accentuated with 
age (Flood & Morley 1998). Interestingly, they present with a lower level of testosterone and 
an increased level of the amyloid precursor protein (APP), a molecule also implicated in AD, 
whereas others have demonstrated that by administering testosterone or antisense APP 
mRNA, the cognition of SAMP8 mice can be ameliorated (Flood & Morley 1998; Morley et 
al. 2012). Here, we found that an expression of P301L mutant human tau is not able to 
exacerbate the SApT behavioural phenotype beyond what is observed for the SAMP8 
parental line. We therefore suggest that SApT animals present a spatial learning deficit that is 
governed by their SAMP8 parental background.   
The data show that the accumulation of hyperphosphorylated tau in the SApT mice 
alters the hyperactive behaviour that characterises the SAMP8 animals, and indicate that this 
alteration is more pronounced with age. This is in accordance with the findings of another 
study on APP/PS1 mice back-crossed for at least five generations onto the SAMP8 
background strain, which also demonstrated in hyperactivity and lower levels of anxiety in 
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the elevated plus maze by 6 months of age (Lok et al. 2013). Moreover, the learning capacity 
of the SApT animals was already greatly reduced due to the SAMP8 background, such that 
we were not able to record a further decreased learning capacity.   
 In summary, by expressing human mutant P301L tau in a senescence-accelerated 
mouse model, we have been able to induce increased tau hyperphosphorylation in two known 
tauopathy-associated brain areas, the amygdala and, to a lesser extent, the hippocampus. We 
observed increased anxiety in the older group of SApT animals, similar to that observed in 
the pR5 mice. However, our novel SApT line did not significantly differ from the senescent 
SAMP8 strain in terms of its learning and memory capacity. We therefore conclude that a 
geriatric condition can cause a pronounced histopathology driven by the P301L tau transgene, 
whereas the presence of a modest tau pathology does not cause more pronounced cognitive 
impairments of the senescence-prone mice. 
 
Experimental procedures 
 
Mouse strains and animal ethics 
 
The human tau hyperphosphorylation-prone pR5 mouse line (Götz et al. 2001) was back-
crossed and maintained on a C57BL/6 background. The senescence accelerated 
SAMP8/TaHsd mice (Takeda et al. 1981) were obtained from Harlan Laboratories. The 
newly established SApT strain was obtained by backcrossing the pR5 mice onto the SAMP8 
background for at least 10 generations prior to analysis (Fig. 1). Animals were housed as 2–5 
animals per cage and maintained under sterile standard conditions, on a 12 h light/dark cycle, 
with food and water provided ad libitum. To evaluate the interrelation between ageing and 
hyerphosphorylated tau accumulation, we divided the animals into two age cohorts, a 
younger group (with a median age of 7.8 months) and an older group (median age of 9.9 
months). Animals of both genders were used for all experiments, which were conducted in 
accordance with the Australian Code of Practice for the Care and Use of Animals for 
Scientific Purposes, with approval from the University of Queensland Animal Ethics 
Committee. 
 
Tissue preparation  
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Mice were intracardially perfused with PBS, after which their brains were collected, and 
divided into the two hemispheres, with the cerebellum being removed. One hemisphere was 
processed for biochemical analyses; the other hemisphere was fixed overnight in 4% 
paraformaldehyde at 4°C and then transferred to PBS for paraffin processing and histological 
analysis.  
 
Western blot analysis 
 
Proteins from brain hemispheres (without the cerebellum) were extracted as previously 
described (Baker & Götz 2016), applying the following modifications. Briefly, brain tissue 
was suspended in 500µL of  radio-immunoprecipitation assay (RIPA) buffer supplemented 
with protease and phosphatase inhibitors (Cell Signalling) and homogenised using a 
TissueLyser machine (Qiagen). The lysates were incubated on ice for 30 min, after which 
they were centrifuged (13,000 x g) at 4°C for 15 min. The supernatant was collected and used 
further.  The protein concentration was determined using the BCA assay (BioRad). The 
proteins were denaturated at 95°C for 10 min in Laemmli buffer supplemented with 5% β-
mercaptoethanol. Protein samples (10 µg) and molecular weight standards were loaded on 
10% SDS-polyacrylamide gels and separated by electrophoresis, followed by transfer to a 
low fluorescence PVDF membrane in Turbo transfer buffer using a semidry system (all 
BioRad). Membranes were incubated for 1 h in Odyssey blocking buffer (Li-Cor 
Biosciences) before overnight incubation at 4°C with primary antibodies and 1 h incubation 
at room temperature (RT) with secondary antibodies. Monoclonal primary antibodies were 
used as follows: HT7 against human tau (0.2 µg/mL; Thermo Scientific #MN1000), Tau5 as 
total tau marker (1:1000; Millipore #MAB361) and the anti-phosphorylated tau antibodies 
AT8 (0.2 µg/mL; Sigma #MN1020), AT180 (0.2 µg/mL; Thermo Scientific #MN1040), and 
AT270 (Thermo Scientific #MN1050). The polyclonal antibodies used were: Ser404 
(ThermoFisher #44-758G), Ser235 (NovusBiologicals #NB100-82241), Ser422 (GeneTex 
#GTX86147) and Gapdh (Millipore ABS16).Corresponding fluorescently labelled secondary 
antibodies were used to visualise the protein bands using a Li-Cor machine, and automated 
quantification was performed using Image Studio Lite v4 (all Li-Cor Biosciences). All 
antibodies were diluted in Odyssey blocking buffer (Li-Cor Biosciences).  
 
Immunohistochemical analysis  
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Immunohistochemistry was performed on 7 μm paraffin sections obtained from hemispheres 
mounted on SuperFrost Plus© electrostatically charged adhesion slides (Thermo Fisher). 
Slides were baked at 65°C for 30 min, followed by removal of paraffin and rehydration by 
immersion in xylene, ethanol solutions and Milli Q water. Antigen retrieval was performed 
by heating sections in citrate buffer in a microwave. Next, sections were blocked with 
blocking buffer (20% foetal bovine serum in 0.05% Triton X100) for 1 h at RT. Tissue 
sections were incubated with primary antibodies (see western blot section for the primary 
antibodies used) diluted in blocking buffer overnight at 4°C, followed by washing and 
endogenous peroxidase block (3% hydrogen peroxidase in PBS) for 10 min. Biotinylated 
secondary antibody (Dako) was applied for 1.5 h at RT, followed by incubation with ABC 
reagent in PBS (Vectastain Elite ABC kit) for 30 min at RT. The antibody complex was 
visualised by adding 3,3’-diaminobenzidine (DAB) substrate (Dako). The colour reaction was 
stopped after 30 s to 10 min by immersion in Milli Q water. The nuclei were counterstained 
with Mayer’s haematoxylin (Dako) and rinsed in running tap water. The sections were 
dehydrated with ascending series of ethanol followed by 100% xylene and mounting in 
Depex resin (Ajax Finechem). Pictures were taken with a Metafer VSlide slidescanner 
(MetaSystems using Zeiss Axio Imager Z2). 
The percentage area of tau-positive immunoreactivity was analysed as described 
previously (Baker & Gotz 2016). Briefly, a minimum of three sections from Bregma -1.34 
nm to -2.06 nm were analysed per animal. Images were deconvoluted and regions of interest 
drawn around the amygdala, hippocampus and cortex using ImageJ. For each stain, the 
threshold for positive labelling was defined as having a DAB intensity three standard 
deviations greater than the mean DAB intensity of sections to which no primary antibody was 
applied. 
 
General behavioural phenotype assessment 
 
To assess the general behavioural phenotype of the mice, a modified SHIRPA protocol as the 
primary screen was used (Rogers et al. 1997). This comprises a battery of tests that provides a 
behavioural and functional profile of the tested animals by assessing the general aspect of the 
mice, as well as various reflexes and basic sensorimotor functions. The SHIRPA protocol 
was conducted on a single day, before the other tests were performed. 
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Assessment of muscle strength and basic motor abilities  
 
Grip strength was measured using a T-shaped bar connected to a digital dynamometer (Ugo 
Basile). Mice were placed in such a way that they grabbed the bar spontaneously. They were 
then gently pulled backwards by the tail until they released their grip. Ten repetitions were 
recorded per mouse. Motor coordination and equilibrium were tested using an accelerating 
Rotarod (Ugo Basile). Mice were tested in four trials, during which the rod was accelerated 
from 4 to 20 rotations per min. Consecutive trials were separated by a 2 min interval. Latency 
to fall off the rod was recorded for up to 5 min. 
 
Anxiety assessment  
 
The elevated plus maze is designed to evaluate anxiety in mice based on their innate 
preference for dark and enclosed spaces (Torres & Escarabajal 2002). The arena consisted of 
four runways arranged perpendicularly, two of which were enclosed and two of which were 
open. Behaviour was recorded by an overhead camera and tracked automatically using the 
EthoVision® software (Noldus). Mice were placed in the arena for 5 min and the percentage 
of time spent in the open arms of the maze was used as a measure of anxiety.  
 
Lerning and memory assessment 
In order to examine spatial memory, mice were assessed using the active place avoidance test  
as previously described (Vukovic et al. 2013). In brief, over five consecutive days mice were 
trained to avoid a fixed punishment sector within an arena continuously rotating at 1 rpm. 
Mice were handled daily three days before training and were habituated to the arena during a 
5 min exploration session the day before training commenced. During the five training days, 
a fixed 60° shock zone extending from the centre point of the arena to the southern side of the 
room was present. Mice were placed in the rotating arena for 10 min each day. Mice that 
entered the designated shock zone would receive a 0.5 mA shock, with an entrance-shock 
delay of 0.5 s, a shock duration of 0.5 s and a 1.5 s interval between shocks.  
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Statistical analysis  
 
Statistical analysis was performed with GraphPad Prism v6 software (GraphPAd Software, 
Inc.), using ANOVA (one- or two-way with multiple comparisons, as appropriate) with post-
hoc analysis using Tukey’s multiple comparisons test. Data are presented as mean ± standard 
error measurement (SEM), with p<0.05 considered significant. 
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Figure legends 
 
Figure 1 
 
Generation of the senescence-accelerated phospho-tau strain (SApT) and experimental 
design. (a) SApT mice were obtained by backcrossing the pR5 strain (C57BL/6, black coat) 
expressing human p301L mutant tau onto the senescence-accelerated prone SAMP8 
background (AKR/J, white coat) for at least 10 generations before analysis. Mice were 
randomly divided into a younger group and an older group based on their age, and were used 
for biochemical and behavioural analyses; (b) Representative HT7, tau5 and Gapdh western 
blots, and quantification of the HT7-positive bands showing expression of human tau in the 
SApT and pR5 mouse lines in the two age groups assessed; y: younger group; o: older group; 
2xANOVA multiple comparisons with a Tukey post-hoc test; ***p<0.001; N=4; data 
presented as mean ± SEM. 
 
Figure 2 
 
Phosphorylation levels in total brain lysates from SApT mice compared with controls. 
(a) Representative AT8 (P-Ser202/P-Ser205), tau5 and Gapdh western blots and their 
quantification ; (b) Representative AT180 (P-Thr231) tau5 and Gapdh western blots and their 
quantification; (c) Representative AT270 (P-Thr181) tau5 and Gapdh western blots and their 
quantification;  (d) Representative Ser235, tau5 and Gapdh western blots and their 
quantification; (e) Representative Ser404, tau5 and Gapdh western blots and their 
quantification; (f) Representative Ser422, tau5 and Gapdh western blots and their 
quantification; y: younger group; o: older group; 2xANOVA multiple comparisons with a 
Tukey post-hoc test; *p<0.05,, *p<0.01, ***p<0.001; N=4; data presented as mean ± SEM. 
 
Figure 3 
 
Tau phosphorylation is most abundant in the amygdala of SApT mice. (a) Representative 
sections stained immunohistochemically with AT8 (P-Ser202/P-Ser205) and their 
quantification, revealing increased immunoreactivity in the amygdala and hippocampus; (b) 
Representative sections stained immunohistochemically with AT180 (P-Thr231)  and their 
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quantification, demonstrating increased immunoreactivity in the amygdala, hippocampus and 
cortex; (c) Representative sections stained immunohistochemically with Ser235  and their 
quantification, demonstrating increased immunoreactivity in the amygdala and cortex; Scale 
bars: 1mm (black bar); y: younger group, o: older group; 2xANOVA multiple comparisons & 
Tukey post-hoc test; ***p<0.001, **p<0.01, *p<0.05; N≥5; data presented as mean ± SEM. 
 
Figure 4 
 
General behavioural assessment of SApT mice reveals no deficits. (a) Only the older 
group pR5 mice show increased body weight; (b) Similar grip strength between SApT mice 
and age-matched SAMP8 and pR5 controls; (c) Similar motor activity in SApT and age-
matched SAMP8 and pR5 controls as assessed by the Rotarod test; 2xANOVA multiple 
comparisons & Tukey post-hoc test; ***p<0.001, **p<0.01, *p<0.05; N≥5; data presented as 
mean ± SEM.  
 
Figure 5 
 
The elevated plus maze test revealed increased anxiety in the old SApT and pR5 mice. 
(a) Cumulative heat maps of the time spent in the open arms of the elevated plus maze by the 
younger and older SAMP8, SApT and pR5 mice; (b) Quantification of the time spent in the 
open arms, revealing a decrease in the older SApT and pR5 groups vs SAMP8 mice; y: 
younger group, o: older group; 1xANOVA ; multiple comparisons & Tukey post-hoc test; ; 
*p<0.05; N=5; data presented as mean ± SEM. 
 
Figure 6 
 
Increased memory deficits in SApT and SAMP8 mice revealed by the active place 
avoidance test. (a) Representative tracing pictures during days 1 and 5 of the trial; (b) 
Quantification of the number of shocks received by the animals during the trial reveals a 
significant difference between the SApT and SAMP8 vs pR5 groups, independent of age; (c) 
Quantification of the time required for the first entry into the shock zone reveals a clear 
difference between the learning status of the older pR5 mice that is restricted to the final trial 
days; (d) The maximum avoidance time of the shock zone reveals a clear difference between 
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the pR5 and  the SApT and SAMP8 groups; ; 2xANOVA multiple comparisons & Tukey 
post-hoc test; ***p<0.001, **p<0.01, *p<0.05; colour of stars: pR5 vs group matching the 
colour; black stars: pR5 vs SApT and pR5 vs SAMP8; N=5; data presented as mean ± SEM. 
	
 
 
 
 
